Less common targeted therapies for CRC include HER2 inhibitors (e.g., trastuzumab, tucatinib, pertuzumab, and trastuzumab deruxtecan) for HER2-amplified (HER2-positive) advanced CRC that is KRAS-WT and BRAF-WT, and BRAF inhibitors (e.g., encorafenib) for metastatic CRC with BRAF-V600E mutation, used in combination with EGFR inhibitor cetuximab (Figure 2) [14,34]. The gene discussed is KRAS; the disease is colorectal carcinoma.